Schwab US Dividend Equity ETF (SCHD) has outperformed SPY year-to-date, widening its lead during recent market volatility. Rising oil prices and 10-year Treasury yields have increased inflation concerns and could delay anticipated Fed rate cuts.Y. Year-to-date 48 companies have a return greater than SPY, while 28 of them have a return that more than double that of the broad market ETF.
When it comes to global defense spending, the “big three” are the U.S., Russia and China. That's unlikely to change.
For investors who favor exchange-traded funds (ETFs), the market has never been more dynamic. Not only do ETFs now outnumber individual stocks, but the sheer versatility of today's funds allows investors to target nuanced strategies, from exposure to thematic trends like the memory chip shortage to increasingly risky leveraged short-term speculation.
Webull just posted its strongest quarter ever, but a closer look at the valuation math reveals a serious tension between the momentum trade and what the stock is actually worth right now.
The AI buildout is creating winners across several key industries, including computing, power machinery, and software. Notably, after strong recent performance, three top names across these spaces just saw large bouts of insider selling, totaling over $450 million.
The biggest AI gains of the next two years may come from names most investors overlook entirely.
Okta, Gartner and Salesforce all crushed earnings, demonstrating strong business, and now stock price momentum.
Artificial intelligence has reshaped the semiconductor and cloud-infrastructure landscape at a pace few investors imagined two years ago.
Seagate has quietly become one of the most important names in the
Q2 2026 was an impressive quarter for many companies, with wave after wave of earnings wins across the S&P 500 in recent weeks. Headlines have focused on AI stock wins, but these companies do not have a monopoly on noteworthy earnings.
Markets are increasingly being shaped by a tug-of-war between inflation, government borrowing, and the enormous pool of financial assets sitting on investors' balance sheets.
Eli Lilly (NYSE:LLY | LLY Price Prediction) just posted one of the most impressive quarters in Big Pharma history.